Brought to you by 
Reliant licenses, then acquires Novartis's DynaCirc
07 Dec 2022
Executive Summary
Reliant Pharmaceuticals (in-licenses branded drugs) acquired two-year exclusive US rights to use, promote, market, sell, and distribute Novartis Pharmaceuticals' DynaCirc (isradipine) family of products to treat hypertension. It paid $47.6mm for the license.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Reliant licenses, then acquires Novartis's DynaCirc
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice